Terminated trial tests new combo for Tough-to-Treat breast cancer
NCT ID NCT03838367
Summary
This study tested whether adding an experimental drug called leronlimab to standard chemotherapy (carboplatin) could help control advanced triple-negative breast cancer that had a specific marker (CCR5+). The first part aimed to find a safe dose, and the second part planned to see if the combination could delay cancer growth. The trial was stopped early with only 10 participants, so no final results on effectiveness are available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CD07 Investigational Site
Chicago, Illinois, 60611, United States
-
Quest Clinical Research
San Francisco, California, 94115, United States
Conditions
Explore the condition pages connected to this study.